Join our community of smart investors

Chi-Med changes Lilly agreement

The drug developer is adapting its 2013 development agreement with US partner Eli Lilly
Chi-Med changes Lilly agreement

Hutchison China Meditech (HCM) has made changes to its 2013 license and collaboration agreement on cancer drug fruquintinib with US partner Eli Lilly (US:LLY). The amendment effectively changes the roles and responsibilities of Chi-Med and Lilly, in China, for the development and commercialisation of fruquintinib, as well as collaborations for the development of fruquintinib with third-party anti-cancer agents and the promotion and distribution rights of fruquintinib.

IC TIP: Buy at 4,300p

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in